Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease

American Journal of Veterinary Research

Volumn 66, Issue 5, 2005, Pages 861-867

  Callan, Mary Beth ^a   Giger, Urs ^a   Catalfamo, James L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Department of Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN; DESMOPRESSIN; POLYMER; VON WILLEBRAND FACTOR;

AGAR GEL ELECTROPHORESIS; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DOG DISEASE; DRUG EFFECT; FEMALE; HEMOSTASIS; MALE; MOLECULAR SIZE; MOLECULAR WEIGHT; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; VON WILLEBRAND DISEASE;

ANIMALS; DEAMINO ARGININE VASOPRESSIN; DOG DISEASES; DOGS; FEMALE; HEMOSTATICS; MALE; MULTIPROTEIN COMPLEXES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

ANIMALIA; CANIS FAMILIARIS;

EID: 20444505227     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.861     Document Type: Article

References (28)

1. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 1996;72:341-348.
2. Ruggeri ZM, Mannucci PM, Lombardi R, et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982;59:1272-1278.
3. Brooks M. von Willebrand disease. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm's veterinary hematology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2000:509-515.
4. Johnstone IB. Plasma von Willebrand factor-collagen binding activity in normal dogs and dogs with von Willebrand's disease. J Vet Diagn Invest 1999;11:308-313.
5. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000;83:127-135.
6. Riddell AF, Jenkins PV, Nitu-Whalley IC, et al. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol 2002;116:187-192.
7. Venta PJ, Li J, Yuzbasiyan-Gurkan V, et al. Mutation causing von Willebrand's disease in Scottish Terriers. J Vet Intern Med 2000;14:10-19.
8. van Oost BA, Versteeg SA, Slappendel RJ. DNA testing for type III von Willebrand disease in Dutch Kooiker dogs. J Vet Intern Med 2004;18:282-288.
9. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000;6: 60-67.
10. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
11. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148-1153.
12. Cattaneo M, Tenconi PM, Alberca I, et al. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990;64:358-360.
13. Cattaneo M, Pareti FI, Zighetti ML, et al. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. J Lab Clin Med 1995;125:540-547.
14. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990;33:39-45.
15. Favaloro EJ, Dean M, Grispo L, et al. Von Willebrand's disease: use of a collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. Am J Hematol 1994;45:205-211.
16. Benson RE, Catalfamo JL, Dodds WJ. A multispecies; enzyme-linked immunosorbent assay for von Willebrand's factor. J Lab Clin Med 1992;119:420-427.
17. Callan MB, Giger U. Effect of desmopressin acetate administration on primary hemostasis in Doberman Pinschers with type-1 von Willebrand disease as assessed by a point-of-care instrument.Am J Vet Res 2002;63:1700-1706.
18. Giger U, Dodds WJ. Effect of desmopressin in normal dogs and dogs with von Willebrand's disease. Vet Clin Pathol 1989;18: 39-42.
19. Kraus KH, Turrentine MA, Jergens AE, et al. Effect of desmopressin acetate on bleeding times and plasma von Willebrand factor in Doberman Pinscher dogs with von Willebrand's disease. Vet Surg 1989;18:103-109.
20. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981;57:1140-1143.
21. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1977;1:869-872.
22. Mannucci PM, Canciani MT, Rota L, et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand disease. Br J Haematol 1981;47:283-293.
23. Mannucci PM, Bettega D, Cattaneo M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A. Br J Haematol 1992;82:87-93.
24. Meyers KM, Wardrop KJ, Dodds WJ, et al. Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman Pinscher dogs. Thromb Res 1990;57:97-108.
25. McCarroll DR, Waters DC, Steidley KR, et al. Canine platelet von Willebrand factor: quantification and multimeric analysis. Exp Hematol 1988;16:929-937.
26. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study Blood 2004;103:2032-2038.
27. Kraus KH, Turrentine MA, Johnson GS. Multimeric analysis of von Willebrand factor before and after desmopressin acetate (DDAVP) administration intravenously and subcutaneously in male Beagle dogs. Am J Vet Res 1987;48:1376-1379.
28. Olsen EHN, McCain AS, Merricks EP et al. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood 2003;102:436-441.